BioCardia Hit With Nasdaq Notice Over $835K Stockholders' Equity vs $2.5M Minimum
BCDA sits 19% above its 52-week low of $0.661.
Summary
Nasdaq notified BioCardia on November 20, 2026 that its $835,000 stockholders' equity is below the $2.5 million continued-listing minimum. The company has until January 4, 2027 to submit a compliance plan, with trading unaffected for now.
Key Events · Legal and Risk Events · BCDA
-
Nasdaq Equity Deficiency Notice Received
Nasdaq notified BioCardia on November 20, 2026 that stockholders' equity of $835,000 as of September 30, 2026 falls short of the $2.5 million minimum required by Listing Rule 5550(b)(1).
-
January 4, 2027 Plan Deadline
The company must give Nasdaq a plan to regain compliance by January 4, 2027; if accepted, Nasdaq may extend up to 180 calendar days from November 20, 2026 to evidence compliance.
-
Cash Runway Collides With Cure Deadline
The 10-Q reported $2.2 million of cash at September 30, 2026 and said operations cannot be funded past January 2027, with the ATM fully used and no shares left under the current shelf — the equity cure Nasdaq wants is the hardest one to execute.
-
Trading Unaffected For Now
The notice has no immediate effect on listing; BCDA continues to trade on the Nasdaq Capital Market, and the company intends to submit a compliance plan and may request a hearing if rejected.
Analysis · BCDA · Life Sciences
BioCardia is back in Nasdaq's crosshairs, this time on the stockholders' equity test rather than the bid price. Equity of $835,000 at September 30, 2026 sits $1.665 million below the $2.5 million minimum, and the company has only until January 4, 2027 to hand Nasdaq a plan. That deadline lands almost exactly when management has said cash runs out — the 10-Q disclosed $2.2 million of cash and an inability to fund operations past January 2027, with the ATM fully used and no shares left under the current shelf. So the fix Nasdaq will want (an equity raise) is the same thing the balance sheet currently can't easily deliver, and any raise would be heavily dilutive at $0.785. Trading continues normally for now, but a rejected plan or a failed hearing puts the listing itself at risk.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BCDA was trading at $0.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.9M. The 52-week trading range was $0.66 to $1.80. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.